Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling

Fig. 7

DCLK1-activated IL-6/STAT3 pathway plays critical roles in CSC-like properties and anti-tumor immunity in TNBC. DCLK1 upregulates IL-6 expression and activates JAK1/STAT3 signaling, which promotes tumor cell stemness and inhibits CD8+ T cell-mediated antitumor immunity. DCLK1-IN-1 may be a promising treatment for TNBC patients with high DCLK1 expressions

Back to article page